NASDAQ:IPSC Century Therapeutics (IPSC) Stock Price, News & Analysis → A lot of people are making this costly mistake (From WealthPress) (Ad) Free IPSC Stock Alerts $4.30 +0.03 (+0.70%) (As of 12:28 PM ET) Add Compare Share Share Today's Range$4.05▼$4.3950-Day Range$3.47▼$5.3252-Week Range$1.28▼$5.51Volume18,444 shsAverage Volume219,822 shsMarket Capitalization$278.73 millionP/E RatioN/ADividend YieldN/APrice Target$14.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Century Therapeutics alerts: Email Address Century Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside234.1% Upside$14.17 Price TargetShort InterestHealthy7.57% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 2 Articles This WeekInsider TradingSelling Shares$127,635 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.02) to ($2.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.89 out of 5 starsMedical Sector714th out of 939 stocksBiotechnology Industry13th out of 24 stocks 3.4 Analyst's Opinion Consensus RatingCentury Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.17, Century Therapeutics has a forecasted upside of 234.1% from its current price of $4.24.Amount of Analyst CoverageCentury Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.57% of the float of Century Therapeutics has been sold short.Short Interest Ratio / Days to CoverCentury Therapeutics has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Century Therapeutics has recently decreased by 6.29%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCentury Therapeutics does not currently pay a dividend.Dividend GrowthCentury Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IPSC. Previous Next 2.8 News and Social Media Coverage News SentimentCentury Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Century Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for IPSC on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Century Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Century Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $127,635.00 in company stock.Percentage Held by InsidersOnly 7.60% of the stock of Century Therapeutics is held by insiders.Percentage Held by Institutions50.20% of the stock of Century Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Century Therapeutics are expected to decrease in the coming year, from ($2.02) to ($2.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Century Therapeutics is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Century Therapeutics is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCentury Therapeutics has a P/B Ratio of 1.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIWarning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…Watch the presentation here About Century Therapeutics Stock (NASDAQ:IPSC)Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.Read More IPSC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IPSC Stock News HeadlinesMarch 11, 2024 | insidertrades.comAdrienne Farid Sells 22,831 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) StockMarch 21, 2024 | americanbankingnews.comCentury Therapeutics, Inc. (NASDAQ:IPSC) Receives $14.17 Consensus Target Price from BrokeragesMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 19, 2024 | markets.businessinsider.comStrong Buy Rating for Century Therapeutics Amid Promising CNTY-101 Developments and Market CatalystsMarch 19, 2024 | americanbankingnews.comCentury Therapeutics' (IPSC) Buy Rating Reaffirmed at HC WainwrightMarch 19, 2024 | globenewswire.comCentury Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceMarch 19, 2024 | americanbankingnews.comHC Wainwright Reaffirms "Buy" Rating for Century Therapeutics (NASDAQ:IPSC)March 19, 2024 | americanbankingnews.comCentury Therapeutics (NASDAQ:IPSC) Rating Reiterated by HC WainwrightMarch 28, 2024 | Crypto 101 Media (Ad)Crypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.March 19, 2024 | americanbankingnews.comCentury Therapeutics (NASDAQ:IPSC) PT Raised to $24.00 at Canaccord Genuity GroupMarch 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Century Therapeutics on Strong Clinical and Financial OutlookMarch 15, 2024 | finanznachrichten.deCentury Therapeutics, Inc.: Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdatesMarch 14, 2024 | investorplace.comIPSC Stock Earnings: Century Therapeutics Misses EPS, Misses Revenue for Q4 2023March 14, 2024 | benzinga.comCentury Therapeutics: Q4 Earnings InsightsMarch 14, 2024 | globenewswire.comCentury Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdatesMarch 11, 2024 | msn.comCentury Therapeutics to Showcase Groundbreaking Cancer Research at AACR Annual Meeting 2024March 9, 2024 | finance.yahoo.comCentury Therapeutics Inc (IPSC) COO Adrienne Farid Sells 53,515 SharesMarch 5, 2024 | globenewswire.comCentury Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual MeetingFebruary 22, 2024 | investorplace.com3 Millionaire-Maker Under-$10 Stocks to Buy in February 2024February 15, 2024 | seekingalpha.comIPSC Century Therapeutics, Inc.February 14, 2024 | investing.comCentury Therapeutics Inc (IPSC)February 1, 2024 | finance.yahoo.comCentury Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceJanuary 22, 2024 | benzinga.comIN8bio's Phase 1 Clinical Trial Of INB-100 Offers Hope To Leukemia Patients With Promising DataDecember 13, 2023 | markets.businessinsider.comHold Rating on Century Therapeutics Amid Early Clinical Data and Market SpeculationDecember 9, 2023 | finance.yahoo.comCentury Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ EditsDecember 8, 2023 | markets.businessinsider.comBuy Rating Affirmed for Century Therapeutics: Promising Clinical Data and Financial Stability Highlight PotentialDecember 7, 2023 | finance.yahoo.comCentury (IPSC) Up 36% on FDA Nod to Begin Phase I Lupus StudySee More Headlines Receive IPSC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Century Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today3/28/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:IPSC CUSIPN/A CIK1850119 Webwww.centurytx.com Phone267-817-5790FaxN/AEmployees163Year FoundedN/APrice Target and Rating Average Stock Price Target$14.17 High Stock Price Target$24.00 Low Stock Price Target$5.00 Potential Upside/Downside+231.8%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-136,670,000.00 Net Margins-6,115.12% Pretax Margin-6,030.96% Return on Equity-54.73% Return on Assets-31.15% Debt Debt-to-Equity RatioN/A Current Ratio9.92 Quick Ratio9.92 Sales & Book Value Annual Sales$2.23 million Price / Sales124.12 Cash FlowN/A Price / Cash FlowN/A Book Value$3.09 per share Price / Book1.38Miscellaneous Outstanding Shares64,820,000Free Float59,892,000Market Cap$276.78 million OptionableOptionable Beta1.29 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Adrienne Farid Ph.D. (Age 62)COO & Head of Early Development Comp: $650.66kMr. Brent Pfeiffenberger M.B.A.Pharm.D., CEO & DirectorMr. Douglas Carr CPAInterim Principal Financial Officer, Senior VP of Finance & Operations and SecretaryDr. Gregory Russotti Ph.D. (Age 57)Chief Technology & Manufacturing Officer Mr. Kenneth J. Dow J.D.Senior VP of General CounselDr. Shane Williams Ph.D.Chief People OfficerDr. Hyam I. Levitsky M.D. (Age 66)President of Research & Development Comp: $502.12kMichael Naso Ph.D.Senior VP of Cell EngineeringDr. Nick Trede M.D.Ph.D., Senior VP & Head of Clinical DevelopmentMore ExecutivesKey CompetitorsCoherus BioSciencesNASDAQ:CHRSSutro BiopharmaNASDAQ:STROGritstone bioNASDAQ:GRTSCompass TherapeuticsNASDAQ:CMPXScilexNASDAQ:SCLXView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 5,483 shares on 3/11/2024Ownership: 1.880%Adrienne FaridSold 22,831 sharesTotal: $117,351.34 ($5.14/share)Goldman Sachs Group Inc.Sold 3,653 shares on 3/1/2024Ownership: 0.075%Abel Hall LLCBought 10,071 shares on 2/28/2024Ownership: 0.017%Virtu Financial LLCBought 14,018 shares on 2/26/2024Ownership: 0.023%View All Insider TransactionsView All Institutional Transactions IPSC Stock Analysis - Frequently Asked Questions Should I buy or sell Century Therapeutics stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Century Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IPSC shares. View IPSC analyst ratings or view top-rated stocks. What is Century Therapeutics' stock price target for 2024? 6 equities research analysts have issued 1 year price targets for Century Therapeutics' stock. Their IPSC share price targets range from $5.00 to $24.00. On average, they predict the company's share price to reach $14.17 in the next twelve months. This suggests a possible upside of 234.1% from the stock's current price. View analysts price targets for IPSC or view top-rated stocks among Wall Street analysts. How have IPSC shares performed in 2024? Century Therapeutics' stock was trading at $3.32 at the start of the year. Since then, IPSC shares have increased by 27.7% and is now trading at $4.24. View the best growth stocks for 2024 here. Are investors shorting Century Therapeutics? Century Therapeutics saw a decrease in short interest in March. As of March 15th, there was short interest totaling 1,640,000 shares, a decrease of 6.3% from the February 29th total of 1,750,000 shares. Based on an average daily volume of 214,300 shares, the short-interest ratio is presently 7.7 days. Approximately 7.6% of the company's shares are short sold. View Century Therapeutics' Short Interest. When is Century Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our IPSC earnings forecast. How were Century Therapeutics' earnings last quarter? Century Therapeutics, Inc. (NASDAQ:IPSC) released its quarterly earnings results on Thursday, March, 14th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.07. The business had revenue of $0.27 million for the quarter, compared to analysts' expectations of $1.69 million. Century Therapeutics had a negative net margin of 6,115.12% and a negative trailing twelve-month return on equity of 54.73%. When did Century Therapeutics IPO? Century Therapeutics (IPSC) raised $201 million in an initial public offering (IPO) on Friday, June 18th 2021. The company issued 10,600,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler served as the underwriters for the IPO. Who are Century Therapeutics' major shareholders? Century Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Avidity Partners Management LP (2.26%), Vanguard Group Inc. (1.88%), Vanguard Group Inc. (1.88%), Federated Hermes Inc. (1.03%), Bridgeway Capital Management LLC (0.20%) and New York Life Investment Management LLC (0.17%). Insiders that own company stock include Adrienne Farid, Douglas Carr, Eli Casdin, Luis Borges and Versant Venture Capital Vi, L. View institutional ownership trends. How do I buy shares of Century Therapeutics? Shares of IPSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IPSC) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Century Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.